In the present clinical study, total 45 patients of Alpartava (menstrul flow
< 60ml -two consecutive cycles, by vaginal pad weight) were managed in three groups viz. 1st study group - Phalkalyan ghrita (Matra basti + oral - PG), 2nd study group - Phalkalyan ghrita (oral - PG) and third control group - Rajahpravartini vati. In 1st study group (n=12), Phalkalyan ghrita was administered by Matra basti in a dose of 60ml/day for 8 consecutive days for 2 cycles along with oral route in a dose of 5 gm per day in divided doses for two months. In 2nd group (n=16), Phalkalyan ghrita was administered by oral route in a dose of 5 gm per day in divided doses for two months and in control group (n=17), Rajahpravartini vati in a dose of 250 gm per day in divided doses for two months was administerd. In all the groups, Ushnodaka as Anupana was used. All the three groups were followed up for two months after withdrawal of trial drugs. Vaginal pad weight was recorded before, during and after therapy. Clinical study of both the study groups has shown increase in the quantity of menstrual flow in patients of Alpartava. This proves Artavajanan and phytoestrogenic property of Phalkalyan ghrita. Three patients of Alpartava conceived during clinical trial, which also shows the fertility enhancing effect of Phalkalyan ghrita.
Key words: Hypomenorrhea, Alpartava, Phalkalyan ghrita, Rajahpravartini vati.